Curative Biotechnology, Inc. (CUBT)
USD 0.01
(5.93%)
USD 0.01
(5.93%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 2.2 Million USD | 117.59% |
| 2022 | 1.01 Million USD | 250.98% |
| 2021 | -670.26 Thousand USD | -267.92% |
| 2020 | 399.15 Thousand USD | 319734.94% |
| 2019 | 124.80 USD | -99.94% |
| 2018 | 198.76 Thousand USD | 0.08% |
| 2017 | 198.61 Thousand USD | 0.08% |
| 2016 | 198.46 Thousand USD | 3.06% |
| 2015 | 192.57 Thousand USD | -21.93% |
| 2014 | 246.66 Thousand USD | -4.05% |
| 2013 | 257.06 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 2.11 Million USD | -3.92% |
| 2024 Q2 | 2.16 Million USD | 2.22% |
| 2023 Q2 | 1.39 Million USD | 9.54% |
| 2023 Q3 | 1.4 Million USD | 0.81% |
| 2023 Q1 | 1.27 Million USD | 25.59% |
| 2023 FY | 2.2 Million USD | 117.59% |
| 2023 Q4 | 2.2 Million USD | 56.9% |
| 2022 Q2 | 454.1 Thousand USD | 394.3% |
| 2022 Q4 | 1.01 Million USD | 19.63% |
| 2022 Q3 | 845.91 Thousand USD | 86.28% |
| 2022 FY | 1.01 Million USD | 250.98% |
| 2022 Q1 | -154.3 Thousand USD | 76.98% |
| 2021 Q1 | -520.6 Thousand USD | -230.43% |
| 2021 FY | -670.26 Thousand USD | -267.92% |
| 2021 Q4 | -670.26 Thousand USD | 8.41% |
| 2021 Q3 | -731.84 Thousand USD | -22.49% |
| 2021 Q2 | -597.47 Thousand USD | -14.76% |
| 2020 Q4 | 399.15 Thousand USD | 977.6% |
| 2020 Q1 | 14.53 Thousand USD | 0.0% |
| 2020 Q2 | 31.73 Thousand USD | 118.37% |
| 2020 FY | 399.15 Thousand USD | 319734.94% |
| 2020 Q3 | 37.04 Thousand USD | 16.72% |
| 2019 Q4 | - USD | 0.0% |
| 2019 FY | 124.80 USD | -99.94% |
| 2018 FY | 198.76 Thousand USD | 0.08% |
| 2017 FY | 198.61 Thousand USD | 0.08% |
| 2016 FY | 198.46 Thousand USD | 3.06% |
| 2015 FY | 192.57 Thousand USD | -21.93% |
| 2014 Q1 | 251.65 Thousand USD | -2.1% |
| 2014 FY | 246.66 Thousand USD | -4.05% |
| 2013 Q1 | 152.71 Thousand USD | 0.0% |
| 2013 Q4 | 257.06 Thousand USD | 0.0% |
| 2013 FY | 257.06 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 168190.153% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 61.016% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 94.854% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 982.133% |
| Rebus Holdings, Inc. | 305 Thousand USD | -621.961% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 134.927% |
| Qrons Inc. | 351.42 Thousand USD | -526.583% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -253.809% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 94.93% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 10889.793% |
| Skye Bioscience, Inc. | -5.72 Million USD | 138.487% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 86.031% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 46.528% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -447.962% |
| SQZ Biotechnologies Company | -36.23 Million USD | 106.076% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 1.795% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -137.491% |
| Mesoblast Limited | 55.85 Million USD | 96.058% |
| Marizyme, Inc. | 18.56 Million USD | 88.142% |
| Genus plc | 190.6 Million USD | 98.845% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 1.514% |
| Pharming Group N.V. | 109.8 Million USD | 97.995% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -155.973% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -81.399% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -223.821% |
| ContraFect Corporation | -6.02 Million USD | 136.541% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -1535.47% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -90.577% |
| IMV Inc. | 7.67 Million USD | 71.293% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 59.978% |
| MultiCell Technologies, Inc. | 90.04 USD | -2445458.641% |
| ONE Bio Corp. | 9.04 Million USD | 75.642% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 400.006% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 82.991% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -60.967% |
| Q BioMed Inc. | 4.06 Million USD | 45.764% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 92.793% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -118.512% |
| Biomind Labs Inc. | 711.4 Thousand USD | -209.527% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 96.363% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -10.133% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 82.806% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -512.155% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -1475.049% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -10983.611% |
| GB Sciences, Inc. | 1.74 Million USD | -26.021% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 1298.109% |
| HST Global, Inc. | 96.79 Thousand USD | -2174.938% |
| CSL Limited | 10.52 Billion USD | 99.979% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -967.798% |
| Halberd Corporation | 144.72 Thousand USD | -1421.535% |
| Enzolytics Inc. | 981.65 Thousand USD | -124.313% |
| Agentix Corp. | 37.63 Thousand USD | -5751.508% |
| Resverlogix Corp. | 6.45 Million USD | 65.866% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 427.146% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.109% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 104.684% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 68.859% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 18.705% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 124.91% |
| AVAX Technologies, Inc. | -5.9 Million USD | 137.301% |
| Zenith Capital Corp. | 10.06 Thousand USD | -21779.779% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.207% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -998.617% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 7.714% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -1238.517% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 12120.859% |
| Kadimastem Ltd | -253.1 Thousand USD | 969.997% |
| Helix BioMedix, Inc. | -2.57 Million USD | 185.679% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 89.14% |
| BioStem Technologies, Inc. | 4.47 Million USD | 50.761% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -994.13% |
| LadRx Corporation | -2.03 Million USD | 208.127% |
| Cell Source, Inc. | 9.23 Million USD | 76.148% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -246.677% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -246.677% |
| NovAccess Global Inc. | 2.17 Million USD | -1.079% |
| Affymax, Inc. | -5.59 Million USD | 139.342% |
| Itoco Inc. | 228.3 Thousand USD | -864.491% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -1519.235% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 55.578% |
| Mobile Lads Corp. | 484.23 Thousand USD | -354.737% |
| CytoDyn Inc. | 20.26 Million USD | 89.132% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 340437.094% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 23858.095% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 71.425% |
| SYBLEU INC | 473.71 Thousand USD | -364.833% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 50.595% |
| International Stem Cell Corporation | 2.59 Million USD | 14.981% |
| Bioxytran, Inc. | 1.89 Million USD | -15.96% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -3428.081% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -0.967% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 35.877% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 74.255% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -185.007% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 276.158% |
| Neutra Corp. | 52.18 Thousand USD | -4119.405% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 188.469% |
| PureTech Health plc | -167.19 Million USD | 101.317% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 999.105% |
| IXICO plc | -4.44 Million USD | 149.543% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 83.342% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 95.986% |
| CSL Limited | 10.52 Billion USD | 99.979% |
| Cellectis S.A. | -43.81 Million USD | 105.025% |